📊 MEDP Key Takeaways
Is Medpace Holdings, Inc. (MEDP) a Good Investment?
Medpace demonstrates strong operational fundamentals with 20% revenue growth, robust 20% operating margins, and exceptional free cash flow generation ($145M, 20.5% of revenue). The company's zero debt, substantial cash reserves ($652.7M), and 20.7% ROE reflect financial strength, though net income growth stagnation despite revenue expansion and liquidity concerns warrant monitoring.
Why Buy Medpace Holdings, Inc. Stock? MEDP Key Strengths
- Strong revenue growth of 20% YoY demonstrates market demand and business momentum
- Exceptional free cash flow generation of $145M (20.5% FCF margin) with minimal capex requirements
- Zero long-term debt with $652.7M cash reserves providing financial flexibility and strategic optionality
- Excellent profitability with 20.0% operating margin and 17.5% net margin indicating operational efficiency
- High ROE of 20.7% demonstrates effective deployment of shareholder capital
MEDP Stock Risks: Medpace Holdings, Inc. Investment Risks
- Current ratio of 0.85x indicates potential short-term liquidity constraint; current assets insufficient to cover current liabilities
- Net income growth of 0% YoY despite 20% revenue growth suggests margin compression or unfavorable operating leverage
- Divergence between strong FCF and flat net income raises questions about earnings quality and accrual management
- CRO sector cyclicality and client concentration risks typical of clinical research outsourcing business
- Insider activity of 12 Form 4 filings in 90 days warrants monitoring for insider confidence signals
Key Metrics to Watch
- Current ratio trajectory and working capital management - resolution of liquidity concern
- Operating margin sustainability with scale and revenue growth continuation
- Free cash flow conversion rate relative to net income to assess quality of earnings
- Client concentration and contract backlog trends to evaluate growth sustainability
- Capital allocation decisions and potential share repurchase activity driving EPS growth
Medpace Holdings, Inc. (MEDP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 20.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
MEDP Profit Margin, ROE & Profitability Analysis
MEDP vs Healthcare Sector: How Medpace Holdings, Inc. Compares
How Medpace Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Medpace Holdings, Inc. Stock Overvalued? MEDP Valuation Analysis 2026
Based on fundamental analysis, Medpace Holdings, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Medpace Holdings, Inc. Balance Sheet: MEDP Debt, Cash & Liquidity
MEDP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Medpace Holdings, Inc.'s revenue has grown significantly by 121% over the 5-year period, indicating strong business expansion. The most recent EPS of $8.88 reflects profitable operations.
MEDP Revenue Growth, EPS Growth & YoY Performance
MEDP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $558.6M | $114.6M | $3.67 |
| Q3 2025 | $533.3M | $88.4M | $3.01 |
| Q2 2025 | $528.1M | $88.4M | $2.75 |
| Q1 2025 | $511.0M | $102.6M | $3.20 |
| Q3 2024 | $492.5M | $61.1M | $2.22 |
| Q2 2024 | $460.9M | $61.1M | $1.93 |
| Q1 2024 | $434.1M | $72.9M | $2.27 |
| Q3 2023 | $383.7M | $49.4M | $2.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Medpace Holdings, Inc. Dividends, Buybacks & Capital Allocation
MEDP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Medpace Holdings, Inc. (CIK: 0001668397)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MEDP
What is the AI rating for MEDP?
Medpace Holdings, Inc. (MEDP) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MEDP's key strengths?
Claude: Strong revenue growth of 20% YoY demonstrates market demand and business momentum. Exceptional free cash flow generation of $145M (20.5% FCF margin) with minimal capex requirements.
What are the risks of investing in MEDP?
Claude: Current ratio of 0.85x indicates potential short-term liquidity constraint; current assets insufficient to cover current liabilities. Net income growth of 0% YoY despite 20% revenue growth suggests margin compression or unfavorable operating leverage.
What is MEDP's revenue and growth?
Medpace Holdings, Inc. reported revenue of $706.6M.
Does MEDP pay dividends?
Medpace Holdings, Inc. does not currently pay dividends.
Where can I find MEDP SEC filings?
Official SEC filings for Medpace Holdings, Inc. (CIK: 0001668397) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MEDP's EPS?
Medpace Holdings, Inc. has a diluted EPS of $4.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MEDP a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Medpace Holdings, Inc. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is MEDP stock overvalued or undervalued?
Valuation metrics for MEDP: ROE of 20.7% (sector avg: 15%), net margin of 17.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy MEDP stock in 2026?
Our dual AI analysis gives Medpace Holdings, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is MEDP's free cash flow?
Medpace Holdings, Inc.'s operating cash flow is $151.8M, with capital expenditures of $6.8M. FCF margin is 20.5%.
How does MEDP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 17.5% (avg: 12%), ROE 20.7% (avg: 15%), current ratio 0.85 (avg: 2).